National Comprehensive Cancer Network
About the NCCN Clinical Practice Guidelines in Oncology™
Recent Updates to NCCN Clinical Practice Guidelines in Oncology™
NCCN Categories of Evidence and Consensus
NCCN Guidelines Steering Committee
Submission Request to the NCCN Guidelines Panels
NCCN Guidelines Panels-Meeting Schedule
NCCN Drugs & Biologics Compendium™
About the NCCN Drugs & Biologics Compendium™
No Longer Recommended Uses
NCCN Chemotherapy Order Templates™
JNCCN – The Journal of the National Comprehensive Cancer Network
JNCCN Task Force Supplements
Clinical Recommendations
NCCN 3rd Annual Congress Hematologic Malignancies
Commercial Support
This Congress is supported by educational grants:
Amgen
Bayer HealthCare Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Cephalon Oncology
Eisai Inc.
Genentech BioOnocology and Biogen Idec
Merck Oncology
Millennium Pharmaceuticals, Inc.
Novartis Oncology
Pharmion Corporation
sanofi-aventis, US
NCCN appreciates that these supporting companies recognize NCCN’s need for autonomy in the development of the content of NCCN programs and resources. All NCCN content is produced completely independently.
Last update 03/17/2008.
Clinicians
Patients/Caregivers
Insurers/Employers/Case Managers
Pharma/Biotech
Industry Analysts